Add time:08/11/2019 Source:sciencedirect.com
Background aimsHematopoietic cell mobilization with granulocyte-colony stimulating factor (G-CSF) and PLERIXAFOR (cas 110078-46-1) results in superior CD34+ cell yield compared with G-CSF alone in patients with myeloma and lymphoma. However, plerixafor-based approaches may be associated with high costs. Several institutions use a “just-in-time” plerixafor approach, in which plerixafor is only administered to patients likely to fail mobilization with G-CSF alone. Whether such an approach is cost-effective is unknown.
We also recommend Trading Suppliers and Manufacturers of PLERIXAFOR (cas 110078-46-1). Pls Click Website Link as below: cas 110078-46-1 suppliers
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View